Press Release | August 1, 2023
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Read More
Press Release | August 1, 2023
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
Read More
Press Release | July 20, 2023
Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations and Topline Results from Phase 2b CODY Study in Gorlin Syndrome
Read More
Press Release | June 28, 2023
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors
Read More
News | June 21, 2023
Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic
Read More
Press Release | June 20, 2023
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
Read More
Press Release | June 15, 2023
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Read More
News | June 15, 2023
ImCheck selected as laureate of the new French Tech 2030 program
Read More
Press Release | June 15, 2023
Walgreens and Freenome Establish Partnership to Increase Diversity in Research for the Early Detection of Cancer
Read More
Press Release | June 5, 2023
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results
Read More
Press Release | June 2, 2023
Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer
Read More
Press Release | June 1, 2023
Dr. Robin Edwards and Dr. David Ferry join Dragonfly’s Clinical Leadership Team to help Manage its Growing Clinical Pipeline
Read More
Press Release | May 30, 2023
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
Read More
Press Release | May 24, 2023
Pyxis Oncology to Acquire Apexigen
Read More
Press Release | May 22, 2023
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
Read More
Press Release | May 22, 2023
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
Read More
Press Release | May 19, 2023
Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
Read More
Press Release | May 19, 2023
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
Read More
Press Release | May 19, 2023
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
Read More
News | May 16, 2023
Cyrus Bio Scientist Erik Procko and the company’s lead ACE2-Fc Fusion protein COVID-19 therapeutic are featured in Science news article
Read More
